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Streptococcus pneumoniae serotype 3, isolated from a
penicillin-allergic patient and initially susceptible to fluoro-
quinolones, macrolides, lincosamides, quinupristin-dalfo-
pristin, and telithromycin, became resistant to all these
drugs during treatment. Mutations in the parC and gyrA and
in the 23S rRNA and the ribosomal protein L22 genes were
detected in the resistant isolates.
M
acrolide antimicrobial drugs and new fluoro-
quinolones have become good therapeutic choices in
the treatment of penicillin-resistant Streptococcus pneumo-
niae infections and in penicillin-allergic patients with
pneumococcal pneumonia. Until now, clinical failures of
fluoroquinolones during treatment of pneumococcal infec-
tions have rarely been reported (1–3) and development of
resistance in S. pneumoniae to quinupristin-dalfopristin
and telithromycin during or after treatment with a
macrolide or a combination of macrolide and quinolone
antibiotics has never been reported.
We describe failure of treatment of pneumococcal
pneumonia in a 71-year-old man, who was allergic to peni-
cillin and had a history of chronic obstructive pulmonary
disease. During treatment, isolates that were susceptible to
levofloxacin, clarithromycin, clindamycin, quinupristin-
dalfopristin, and telithromycin became resistant.
The Study
S. pneumoniae were identified to the species level by
their colony morphology, optochin sensitivity, and the bile
solubility tests. Serotyping was performed by the Quellung
reaction (Quellung antisera, Staten Seruminstitut,
Copenhagen). MICs of the antibiotics and criteria of sus-
ceptibility and resistance, otherwise not indicated, were
those of the broth microdilution procedure described by
the National Committee for Clinical LaboratoryStandards
(NCCLS) (4). The agar dilution method (5) and the E-test,
as referred to in Table 1, were performed to expand the
range of dilutions available in the broth microdilution
trays. No discordance was observed in the susceptibility
results, which were obtained by using the broth microdilu-
tion, the agar dilution, or the elution E-test. 
Molecular typing methods (pulsed-field gel elec-
trophoresis [PFGE], BOX-polymerase chain reaction
[PCR], and multilocus sequence typing) of the isolates
were performed according to previously described proto-
cols (6). Presence of the mefA, ermB, and ermA (ermTR)
genes and point mutations at Ser-79 in the parC and at Ser-
81 in the gyrA genes were detected as previously described
(6). Fragments of the domains II and V of the 23S rRNA
genes and of the genes encoding ribosomal proteins L4 and
L22 were amplified by using the primers and conditions
previously described (7,8). Amplification products were
sequenced after purification. 
Case Description
In January 2002, a 71-year-old man, who was allergic
to penicillin and had a history of chronic obstructive pul-
monary disease, was hospitalized due to pneumonia. The
first  S. pneumoniae strain was isolated from sputum
obtained before antibiotic treatment with intravenous lev-
ofloxacin (500 mg once a day for 13 days) was begun. On
day 4, intravenous clarithromycin (500 mg twice a day)
was added but withdrawn after 4 doses. On day 14, clini-
cal and radiologic conditions had deteriorated, and treat-
ment was changed to intravenous clarithromycin (500 mg)
and intravenous ciprofloxacin (200 mg) twice a day for 7
days. On the same day, a second pneumococcal isolate
resistant to levofloxacin and clarithromycin but suscepti-
ble to clindamycin was obtained (Table 1). The MIC of
clarithromycin for this second isolate was 2 µg/mL; by the
double-disk test (9) showed that the susceptibility of clin-
damycin was not modified after the erythromycin induc-
tion. Initially, this second isolate was incorrectly reported
as clarithromycin susceptible because of an erroneous
record of the result of the disk-diffusion method. On day
24, the patient was discharged with oral clarithromycin.
Twenty-four hours later, the patient was readmitted with
exacerbation of the respiratory infection and cor pul-
monale, and two pneumococcal isolates resistant to lev-
ofloxacin, clarithromycin, and clindamycin were found
within 6 hours. The patient received trimethoprim-sul-
famethoxazole for 5 days; a fifth pneumococcal isolate
was found from a pleural effusion specimen. The pneumo-
nia completely resolved after 10 days of treatment with
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País Vasco, San Sebastián, Spainvancomycin. The five S. pneumoniae serotype 3 isolates
recovered over a 32-day period had the same PFGE, BOX-
PCR patterns, and multilocus sequence typing (ST180)
results. 
All S. pneumoniae isolates were susceptible to peni-
cillin (MIC <0.03  µg/mL), trimethoprim-sulfamethoxa-
zole (MIC <0.5/9.5 µg/mL), tetracycline (MIC <2 µg/mL),
chloramphenicol (MIC <2  µg/mL), and vancomycin
(MIC=0.5 µg/mL). The first isolate was susceptible to both
macrolides and fluoroquinolones. This isolate had a lev-
ofloxacin MIC of 2 µg/mL, confirmed by all susceptibility
methods used (E-test, broth microdilution, and agar dilu-
tion), although it had a point mutation in the gyrA gene, as
shown in Table 2. 
For the second isolate, MICs of macrolides, quin-
upristin-dalfopristin, and telithromycin were higher than
those for the first isolate, and a 18-base insert in the
sequence of the gene encoding the ribosomal protein L22
was detected. The result, deduced from the corresponding
ribosomal protein, was a six–amino acid (RTAHIT) inser-
tion between amino acids T108 and V109 (GenBank
accession no. AY140892). The third and fourth isolates,
with resistance to macrolides, clindamycin, quinupristin-
dalfopristin, and the highest telithromycin MICs of all the
isolates, had an A2058G (Escherichia coli numbering)
mutation in the sequence of the gene corresponding to the
domain V of the 23S rRNA as well as the 6–amino acid
insert in the ribosomal protein L22. The four alleles encod-
ing the 23S rRNA gene had the A2058G mutation. The
sequences of the fifth isolate, resistant to macrolide antibi-
otics and clindamycin, with an intermediate susceptibility
to quinupristin-dalfopristin, indicated a mutation at posi-
tion 2058 of domain V, but no insert was found in the ribo-
somal protein L22. 
Conclusions
Since the introduction of antimicrobial drugs in thera-
py, S. pneumoniae has shown a strong ability to acquire
resistance to the progressive introduction of new antibi-
otics to treat it. 
Surveillance studies suggest that the levels of resistance
to macrolide antibiotics in S. pneumoniae are high and are
still rising (9,10). Ketolides, of which telithromycin is the
first to be registered for clinical use, and quinupristin-dal-
fopristin are new compounds belonging to the macrolide-
lincosamide-streptogramin B (MLSb) class of antimicro-
bial agents. One of the main advantages attributed to these
two new families of antibiotics is their ability to retain
activity against most resistant pneumococcal isolates (11).
Recently, mutations in the 23S rRNA genes and in riboso-
mal proteins L4 and L22 have been identified in
macrolide-resistant S. pneumoniae, although the predomi-
nant mechanisms of resistance are mediated by ermB or by
mefA genes (12). The combination of the mutation in the
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Table 1. In vitro antibiotic susceptibilities determined by agar dilution in Streptococcus pneumoniae isolates 
MIC (µg/mL) for each isolate/specimen collected, by date 
Drug 
1st isolate/sputum,  
1-26-2002 
2nd isolate/sputum,  
2-8-2002 
3rd isolate/sputum,  
2-20-2002 
4th isolate/sputum, 
2-20-2002 
5th isolate/pleural fluid, 
2-26-2002 
Ciprofloxacin  2  32  16  16  16 
Levofloxacin  2  16  16  16  16 
Moxifloxacin  1  4  4  4  4 
Gemifloxacin  0.06  0.5  0.5  0.5  0.5 
Erythromycin (14-m
  macrolide)  <0.25  2  >128  >128  >128 
Clarithromycin (14-m
 macrolide)  <0.25  2  >128  >128  >128 
Azithromycin (15-m
 macrolide)  0.5  4  >128  >128  >128 
Midekamycin (16-m macrolide)  <0.5  4  128  64  16 
Clindamycin  <0.25  ≤0.25  16  16  16 
Quinupristin-dalfopristin 
a  1  32  >32  >32  2 
Telithromycin  ≤0.12  2  8  16  0.5 
a Determined by E-test; m, membered. 
Table 2. Point mutations in fluoroquinolone targets and macrolide-lincosamide-streptogramin-resistance determinants and ribosomal 
mutations in Streptococcus pneumoniae isolates 
Location  1st isolate  2nd isolate  3rd isolate  4th isolate  5th isolate 
parC  -  Ser-79  Ser-79  Ser-79  Ser-79 
gyrA  Ser-81  Ser-81  Ser-81  Ser-81  Ser-81 
ermA, ermB and mefA genes  -  -  -  -  - 
Ribosomal protein L4  -  -  -  -  - 
Amino acids insert in ribosomal protein L22  -  RTAHIT
a  RTAHIT  RTAHIT  - 
23S rRNA gene (domain II)  -  -  -  -  - 
23S rRNA gene (domain V)  -  -  A2058G  A2058G  A2058G 
aSequence data GenBank AY140892. domain V of the 23S rRNA and the insertion in the L22
ribosomal protein gene has not been previously described
in  S. pneumoniae isolated in vivo or in vitro. In these
strains, a high level of resistance to 14-, 15-, and 16-mem-
bered ringmacrolides and to clindamycin and resistance to
quinupristin-dalfopristin and telithromycin were observed.
The continued use of clarithromycin in the presence of an
isolate with an insertion in the L22 ribosomal protein gene
may have led to the selection of the isolates with the dou-
ble mutations, L22 and 23S rRNA genes, associated with
combined resistance to telithromycin and quinupristin-dal-
fopristin, although neither of these antibiotics was used.
The A2058G mutation in all four 23S rRNA genes alone
slightly increased both quinupristin-dalfopristin and
telithromycin MICs as seen in the fifth isolate. The L22
insertion alone, as observed in the second isolate, was
enough to confer a high level of quinupristin-dalfopristin
resistance and also increased the telithromycin MIC to 2
µg/mL. The combination of both mutations (L22 insertion
and A2058G mutation in the 23S rRNA genes) led to high
level of resistance to telithromycin and increased the quin-
upristin-dalfopristin MIC (third and fourth isolates).
The first isolate was susceptible to all antibiotics tested,
and although it had a point mutation in the gyrA gene, it
had no phenotypic expression. In mutants obtained in
vitro, other authors observed point mutation in the gyrA
gene without mutation in the parC gene with or without
phenotypic expression of quinolone resistance (13).
Nevertheless, using fluoroquinolones to treat a strain that
had an existing, but unapparent, first-step mutation in the
gyrA gene, probably favored the development of the high
level of resistance to fluoroquinolones observed in the later
isolates. Fluoroquinolone resistance in clinical isolates of
S. pneumoniae is still infrequent, but in some places, the
resistance has been increasing (9,14–16). 
Until now, most erythromycin- or fluoroquinolone-
resistant pneumococci had belonged to only a few
serotypes. Finding an erythromycin-resistant serotype 3
was unusual, and the isolation of a fluoroquinolone-resist-
ant serotype 3 S. pneumoniae was the exception, if ever
reported. Penicillin or another appropriate β-lactam antibi-
otic could have been a valid therapeutic option in the
absence of allergy to penicillin. Serotype 3 is considered
the most virulent of S. pneumoniae serotypes, and it is
commonly associated with invasive disease in adults. Most
serotype 3 isolates have broad antibiotic susceptibility
(17). A fatal infection associated with a multiply drug-
resistant S. pneumoniae serotype 3 was first reported in
1988 (18). This strain was resistant to erythromycin, clin-
damycin, and tetracycline.
The therapeutic failure and selection of resistance to
several antibiotics by S. pneumoniae, the emergence of
new mechanisms of resistance to macrolides in clinical
isolates of S. pneumoniae, and the appearance of multidrug
resistance in a serotype 3 isolate (ST180) evoke concern.
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